For example, the FLOW trial demonstrated that GLP-1 medications can slow CKD progression and lower the risk of kidney failure
evaluating metformin, liraglutide, and combination therapy (metformin 1000 mg BID + liraglutide 1.2 mg/day), only the latter treatment resulted in significant decrease in body weight and androstenedione levels [61]
However, the effects of GLP-1 on the peripheral nervous system and its relationship with pain modulation remain largely unexplored
PGC-1 is a common target of the two metabolic sensors, and has been shown to have protective effects in patients with metabolic diseases [29]
[DOI] [PMC free article] [PubMed] [Google Scholar] 63.Kahn SE, et al
This consensus-based guidance, which includes an outline of eight key nutritional priorities to support patients on GLP-1 medications, reflects the top interdisciplinary recommendations to help clinicians support patients receiving GLP-1 receptor agonists for obesity care with evidence-based nutritional and behavioral strategies
